CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Imagion Biosystems Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Imagion Biosystems Ltd
Level 8, 55 Bourke Street
MELBOURNE, VIC  3000  Australia Ticker: IBXIBX
Business Summary
Imagion Biosystems Limited is a medical imaging company engaged in developing medical imaging technologies for various cancer types. The Company uses bio-safe magnetic nanoparticles to detect cancer and other diseases. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. The Company operates through Research and Development segment. It is advancing clinical development of its MagSense platform technology to revolutionize cancer diagnosis, introducing molecular imaging to Magnetic resonance imaging (MRI). The Company’s lead program has demonstrated its technology embodied in MagSense HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Its MagSense pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board , Managing Director RobertProulx 6/20/2023 2/1/2015
Chief Development Officer YaliaJayalakshmi 9/1/2021 9/1/2021
Non-Executive Director MelanieLeydin 7/31/2024 5/10/2024
Non-Executive Director BrettMitchell 6/14/2024 6/14/2024

Business Names
Business Name
IBX
IBXDA

General Information
Outstanding Shares: 32,646,551 (As of 6/30/2024)
Shareholders: 7,971
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024